FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML
Original Publication Date
Article Source
External Web Content
The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy. The FDA has granted a fast track designation for…
